Micafungin Pharmacenter (Micafungin)

Micafungin blocks the fungal enzyme β‑1,3‑D‑glucan synthase, preventing the formation of 1,3‑β‑D‑glucan, an essential polymer of the fungal cell wall. The resulting weakened wall cannot maintain osmotic balance, leading to cell lysis and death of susceptible Candida organisms.

The dosing regimen for Micafungin Pharmacenter is determined by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and other clinical factors. No fixed dose is provided here; the prescriber sets the appropriate infusion rate and duration.

Safety data for micafungin in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the Micafungin Pharmacenter product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and necessary import documentation.

Micafungin belongs to the echinocandin class, which differs from azole antifungals such as fluconazole. Echinocandins target the fungal cell wall, offering rapid fungicidal activity and a lower risk of drug‑drug interactions, whereas azoles inhibit ergosterol synthesis and are often fungistatic. Micafungin is frequently preferred for azole‑resistant Candida or in patients with significant drug interaction concerns.

Micafungin Pharmacenter must be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If the product reaches room temperature for a short period, it may be used promptly, but it should be returned to refrigeration as soon as possible.

Micafungin Pharmacenter is administered as an intravenous infusion. The solution is diluted in an appropriate compatible IV fluid and infused over a period typically ranging from 30 to 60 minutes, depending on the prescribed dose and clinical protocol. Administration should be performed by qualified healthcare personnel in a controlled setting.

Serious adverse events associated with micafungin include severe hepatic dysfunction, anaphylactic or severe hypersensitivity reactions, and rare skin disorders such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. Patients should be monitored for signs of liver injury, rash, or respiratory distress, and treatment should be discontinued if any of these events occur.

Micafungin is contraindicated in individuals with a known hypersensitivity to micafungin or any component of the formulation. Caution is also advised for patients with pre‑existing severe liver disease, and it should be avoided in those receiving other echinocandin agents due to the risk of additive toxicity.